CN103957925A - 具有γ干扰素的抗原呈递癌症疫苗 - Google Patents

具有γ干扰素的抗原呈递癌症疫苗 Download PDF

Info

Publication number
CN103957925A
CN103957925A CN201280051821.7A CN201280051821A CN103957925A CN 103957925 A CN103957925 A CN 103957925A CN 201280051821 A CN201280051821 A CN 201280051821A CN 103957925 A CN103957925 A CN 103957925A
Authority
CN
China
Prior art keywords
cells
melanoma
ifn
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280051821.7A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁·康福思
罗伯特·迪尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Priority to CN201610301904.7A priority Critical patent/CN105999249A/zh
Priority to CN201510706438.6A priority patent/CN105288602A/zh
Publication of CN103957925A publication Critical patent/CN103957925A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280051821.7A 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗 Pending CN103957925A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610301904.7A CN105999249A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201510706438.6A CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2012/061294 WO2013059778A2 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510706438.6A Division CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610301904.7A Division CN105999249A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗

Publications (1)

Publication Number Publication Date
CN103957925A true CN103957925A (zh) 2014-07-30

Family

ID=48141460

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201280051821.7A Pending CN103957925A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201280051799.6A Pending CN103917246A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗
CN201510706438.6A Pending CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610301904.7A Pending CN105999249A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610218244.6A Withdrawn CN105861437A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201280051799.6A Pending CN103917246A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗
CN201510706438.6A Pending CN105288602A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610301904.7A Pending CN105999249A (zh) 2011-10-20 2012-10-22 具有γ干扰素的抗原呈递癌症疫苗
CN201610218244.6A Withdrawn CN105861437A (zh) 2011-10-20 2012-10-22 抗原呈递癌症疫苗

Country Status (11)

Country Link
US (2) US20140308316A1 (cg-RX-API-DMAC7.html)
EP (2) EP2768534A4 (cg-RX-API-DMAC7.html)
JP (2) JP2014530627A (cg-RX-API-DMAC7.html)
KR (2) KR20150004791A (cg-RX-API-DMAC7.html)
CN (5) CN103957925A (cg-RX-API-DMAC7.html)
AU (2) AU2012325764A1 (cg-RX-API-DMAC7.html)
CA (2) CA2852960A1 (cg-RX-API-DMAC7.html)
HK (2) HK1201176A1 (cg-RX-API-DMAC7.html)
IL (2) IL232172A0 (cg-RX-API-DMAC7.html)
SG (4) SG11201401631VA (cg-RX-API-DMAC7.html)
WO (2) WO2013059784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
SG11201401631VA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
US20190147976A1 (en) * 2016-05-05 2019-05-16 Nantomics, Llc Checkpoint failure and methods therefor
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106778A1 (en) * 2001-12-21 2004-06-03 Fagan Richard Joseph Interferon gamma-like protein
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830470A (en) * 1992-09-07 1998-11-03 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7988963B1 (en) 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
KR101374091B1 (ko) 2005-07-29 2014-03-17 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
CA2628477A1 (en) * 2005-11-07 2007-05-10 Bc Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
SG11201401631VA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106778A1 (en) * 2001-12-21 2004-06-03 Fagan Richard Joseph Interferon gamma-like protein
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
US9555058B2 (en) 2017-01-31
SG10201508535RA (en) 2015-11-27
IL232172A0 (en) 2014-06-30
JP2014533938A (ja) 2014-12-18
EP2768519A4 (en) 2015-07-01
EP2768519A2 (en) 2014-08-27
IL232173A0 (en) 2014-06-30
SG10201602424RA (en) 2016-05-30
WO2013059778A2 (en) 2013-04-25
EP2768534A1 (en) 2014-08-27
WO2013059778A3 (en) 2013-07-04
CN103917246A (zh) 2014-07-09
WO2013059784A1 (en) 2013-04-25
US20140308316A1 (en) 2014-10-16
JP2014530627A (ja) 2014-11-20
CA2852967A1 (en) 2013-04-25
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
CA2852960A1 (en) 2013-04-25
KR20150004791A (ko) 2015-01-13
AU2012325764A1 (en) 2014-04-24
NZ623915A (en) 2016-02-26
SG11201401631VA (en) 2014-05-29
CN105999249A (zh) 2016-10-12
CN105288602A (zh) 2016-02-03
CN105861437A (zh) 2016-08-17
EP2768534A4 (en) 2015-04-01
HK1201176A1 (en) 2015-08-28
NZ623917A (en) 2016-09-30
SG11201401632WA (en) 2014-05-29
AU2012325758A1 (en) 2014-04-24
HK1201175A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
US11096996B2 (en) Cancer vaccines and vaccination methods
US9555058B2 (en) Antigen presenting cancer vaccine
Kim et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Li et al. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy
US20110129503A1 (en) Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
AU2023208190B2 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
Hüttner et al. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
NZ623917B2 (en) Antigen presenting cancer vaccine
Dahlfrancis In Vitro Effects of the Second-Generation Proteasome Inhibitor Carfilzomib on Human Monocyte-Derived Dendritic Cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151021

Address after: American New York

Applicant after: CALIFORNIA STEM CELL INC.

Address before: American California

Applicant before: CALIFORNIA STEM CELL INC.

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140730

WD01 Invention patent application deemed withdrawn after publication